Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 12/20 | 0.58 |
| ▸ | BCHE | P06276 | 9/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10152999 | 0.82 | KDM4E (0.54) | ACHEHTTSMN1; SMN2L3MBTL1LMNA | |
| SCHEMBL20206848 | 0.82 | ACHE (0.41) | ACHEBCHEHTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL26521879 | 0.80 | ACHE (0.39) | ACHEHTTLMNAALDH1A1 | |
| SCHEMBL29654960 | 0.79 | ACHE (0.63) | ACHEBCHEHTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL356804 | 0.79 | ACHE (0.63) | ACHEBCHEHTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL7816047 | 0.79 | HPGD (0.51) | HTTSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL806191 | 0.79 | ACHE (0.39) | ACHEBCHEHTTLMNAALDH1A1 | |
| SCHEMBL2739323 | 0.79 | ADRA2A (0.43) | ACHEHTTLMNAALDH1A1 | |
| SCHEMBL11135055 | 0.78 | ACHE (0.53) | ACHEBCHEHTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL19121433 | 0.77 | ACHE (0.60) | ACHEBCHEHTTSMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115975202-A | Siloxane-modified fluorine-containing antibacterial polymethyl siloxane with antibacterial hydrophobic function and preparation method and application thereof | 苏州东杏新材料科技有限公司 | 2023-04-18 | — | — | CN | claimed |
| CN-115975202-A | Siloxane-modified fluorine-containing antibacterial polymethyl siloxane with antibacterial hydrophobic function and preparation method and application thereof | 苏州东杏新材料科技有限公司 | 2023-04-18 | — | — | CN | disclosed |
| US-20220031908-A1 | Injectable Therapeutic Biocompatible Co-Polymers and Methods of Making and Using Same | MOREHOUSE COLLEGE | 2022-02-03 | — | — | US | disclosed |
| US-20180147318-A1 | Injectable Therapeutic Biocompatible Co-Polymers and Methods of Making and Using Same | MOREHOUSE COLLEGE | 2018-05-31 | — | — | US | disclosed |
| US-20180147318-A1 | Injectable Therapeutic Biocompatible Co-Polymers and Methods of Making and Using Same | MOREHOUSE COLLEGE | 2018-05-31 | — | — | US | disclosed |
| WO-2016187327-A1 | INJECTABLE THERAPEUTIC BIOCOMPATIBLE CO-POLYMERS AND METHODS OF MAKING AND USING SAME | MENDENHALL JUANA (US) | 2016-11-24 | — | — | WO | disclosed |
| EP-1053744-B1 | Substituted phenols as fragrance, flavor and antimicrobial compounds | TAKASAGO PERFUMERY CO LTD (JP) | 2005-04-27 | — | — | EP | disclosed |
| EP-1053744-A2 | Substituted phenols as fragrance, flavor and antimicrobial compounds | Takasago International Corporation (JP) | 2000-11-22 | — | — | EP | disclosed |
| US-6110888-A | PHENOL SUBSTITUTED WITH ONE OF: PROPYL OR PROPENYL; ONE OF: HYDROGEN OR ALKYL; AND ONE TO THREE C3-C5 ALKYL GROUPS; FRAGRANCE AND ANTIMICROBIAL PROPERTIES; USE SUCH AS IN MOUTHWASHES | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2000-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180147318-A1 | Injectable Therapeutic Biocompatible Co-Polymers and Methods of Making and Using Same | CD44, COL2A1, MMP1 | ACHE 1432/4885BCHE 1606/4885HTT 392/4885 |
| US-20220031908-A1 | Injectable Therapeutic Biocompatible Co-Polymers and Methods of Making and Using Same | CD44, COL2A1, MMP1 | ACHE 1543/4885BCHE 1588/4885HTT 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.